Project Grant K01DK147856

This $156,510 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research conducted by Massachusetts General Hospital to develop precision metabolic risk stratification tools for individuals with Major Depressive Disorder (MDD). The award, which commenced July 1, 2026, and extends through March 31, 2030, funds the validation and clinical implementation of multi-omics approaches—including polygenic scores and metabolomic signatures—to identify Type 2 Diabetes (T2D) risk in psychiatric populations, with particular attention to medication-induced metabolic effects from selective serotonin reuptake inhibitor (SSRI) exposure.

The deliverables under this grant include: (1) validation of multi-omics risk scores in SSRI-naïve MDD patients to establish baseline T2D susceptibility; (2) characterization of SSRI-induced metabolic sensitivity through biomarker identification during the first year of MDD diagnosis; and (3) development and external validation of clinically implementable risk stratification models that integrate multimodal metabolic and clinical data. These products are designed to provide clinicians with evidence-based frameworks for T2D prevention and monitoring at the point of MDD diagnosis, addressing a critical gap in the systematic metabolic surveillance of psychiatric patients on antidepressant therapy.